Crossmark

Correction: Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM)

Crossref DOI link: https://doi.org/10.1007/s12282-024-01632-z

Published Online: 2024-09-20

Published Print: 2024-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Nakayama, Takahiro

Niikura, Naoki

Yamanaka, Takashi

Yamamoto, Mitsugu

Matsuura, Kazuo

Inoue, Kenichi

Takahara, Sachiko

Nomura, Hironori

Kita, Shosuke

Yamaguchi, Miki

Aruga, Tomoyuki

Shibata, Nobuhiro

Shimomura, Akihiko

Ozaki, Yuri

Sakai, Shuji

Takiguchi, Daisuke

Takata, Takehiko

Bastanfard, Armin

Shiosakai, Kazuhito

Tsurutani, Junji
License Information

Text and Data Mining valid from 2024-09-20

Version of Record valid from 2024-09-20
More Information

Article History

First Online: 20 September 2024

Document is current

Any future updates will be listed below